FRAMINGHAM, Mass.--Genzyme Molecular Oncology here and Bayer have inked an agreement that will allow Bayer the use of Genzyme Molecular Oncology's patented Serial Analysis of Gene Expression (SAGE) technology.
Bayer will utilize SAGE to identify genes that may have importance in drug development. Financial terms of the agreement were not disclosed.
SAGE is a patented method of simultaneously detecting and measuring the expression levels of virtually all genes expressed in a cell at a given time and can be used in a variety of applications to identify disease-related genes, analyze the effect of drugs on tissues, and provide insight into disease pathways. Because SAGE is a high-throughput method, it may be used to detect differences in rarely expressed but highly significant genes, according to Genzyme.